A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Public ClinicalTrials.gov record NCT03316794. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).
Study identification
- NCT ID
- NCT03316794
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 4, 2018 (Actual)
- Primary completion
- Oct 5, 2018 (Actual)
- Completion
- Oct 5, 2018 (Actual)
- Last update posted
- Dec 17, 2018
2018
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago /ID# 169231 | Chicago | Illinois | 60637-1443 | — |
| Washington University School /ID# 169177 | St Louis | Missouri | 63108 | — |
| Memorial Sloan Kettering /ID# 201016 | New York | New York | 10065 | — |
| Gabrail Cancer Center Research /ID# 168756 | Canton | Ohio | 44718 | — |
| Oklahoma University /ID# 200937 | Oklahoma City | Oklahoma | 73104 | — |
| Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233 | Nashville | Tennessee | 37203 | — |
| Baylor University /ID# 169860 | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center /ID# 169232 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03316794, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2018 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03316794 live on ClinicalTrials.gov.